In mice, liver-specific Lpl overexpression leads to a doubling of liver triglyceride content and insulin resistance (Kim et al., 2001), suggesting that a reduction in Lpl, such as observed with praliciguat treatment, might be involved in reducing insulin resistance or might be a marker of improved insulin sensitivity. The gene discussed is INS; the disease is Insulin resistance.